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Objective: The aim of this study was to develop a simple phenotypic algorithm that can 26 
capture the underlying clinical and hormonal abnormalities to help in the diagnosis and risk 27 
stratification of PCOS. Methods: The study consisted of 111 women with PCOS fulfilling 28 
the Rotterdam diagnostic criteria and 67 women without PCOS. A Firth’s penalised logistic 29 
regression model was used for independent variable section. Model optimism, discrimination 30 
and calibration were assessed using bootstrapping, area under the curve (AUC) and Hosmer-31 
Lemeshow statistics, respectively. The Prognostic index (PI) and risk score for developing 32 
PCOS was calculated using independent variables from the regression model. Results: Firth 33 
penalised logistic regression model with backward selection identified 4 independent 34 
predictors of PCOS namely, free androgen index [Beta 0.30(0.12), p=0.008], 17-OHP 35 
[Beta=0.20(0.01), P=0.026], anti-mullerian hormone (AMH) [Beta=0.04(0.01) p<0.0001], 36 
and waist-circumference [Beta=0.08(0.02), p<0.0001]. The model estimates indicated high 37 
internal validity (minimal optimism on 1000-fold bootstrapping), good discrimination ability 38 
(bias corrected c-statistic=0.90) and good calibration (Hosmer–Lemeshow chi-39 
squared=3.7865). PCOS women with a high risk score (q1+q2+q3 vs. q4) presented with a 40 
worse metabolic profile characterised by a higher 2-hour glucose (p=0.01), insulin 41 
(p=0.0003), triglycerides (p=0.0005), C-reactive protein (p<0.0001) and low HDL-42 
cholesterol (p=0.02) as compared to those with lower risk score for PCOS. Conclusion: We 43 
propose a simple 4-variable model, which captures the underlying clinical and hormonal 44 






























































abnormalities in PCOS and can be used for diagnosis and metabolic risk stratification in 45 
women with PCOS.46 
































































Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting 49 
up to 20% of reproductive-aged women of (1, 2).  There are three available diagnostic criteria 50 
for PCOS; the National Institute of Health (NIH) (3), ESHRE/ASRM Rotterdam consensus 51 
criteria (4) and the androgen excess and PCOS society (AES)(5). Biochemical 52 
hyperandrogenism is a common component of each of three criteria and can be assessed by 53 
using a variety of assays to test for relevant biomarkers in serum and/or saliva including 54 
serum levels of total testosterone (TT), free T, androstenedione, and dehydroepiandrosterone 55 
sulphate (DHEAS) or by calculating available indices such as free androgen index. This 56 
plethora of available androgen biomarkers and indices in combination with the current little 57 
guidance on cut-offs indicative of androgen excess in the PCOS guidelines (3-5) contribute to 58 
diagnosis- and risk stratification- related uncertainties.  FAI is commonly used to define 59 
hyperandrogenemia in the diagnosis of PCOS. However, recent data (6) shows that FAI is not 60 
a reliable indicator of free T when sex hormone binding globulin (SHBG) concentration is 61 
low and hence can misclassify women who are being investigated for PCOS. Clinical 62 
hyperandrogenemia, characterised by the presence of hirsutism is recommended as a 63 
substitute of biochemical hyperandrogenemia in the current guidelines but this can often  be 64 
unreliable due to wide inter-observer variation and ethnic variations (7) . While the focus has 65 
been placed upon biochemical and clinical hyperandrogenemia for the diagnosis of PCOS, 66 
recent data by our group (8) and others (9) have shown that elevated levels of anti-Mullerian 67 
hormone (AMH), a surrogate measure of follicle count on ultrasound, can be an important 68 
supplement to the hormonal parameters used in the diagnosis of PCOS.  While PCOS is a 69 
diagnosis of exclusion, the diagnosis can often be challenging, given the presentation of this 70 
syndrome as a spectrum of clinical features and metabolic abnormalities in the affected 71 






























































patients, rather than the presence of a single unified entity, PCOS. The aim of this study was 72 
to use relevant biochemical markers and quantifiable clinical features to derive a risk score 73 
that can capture the entire PCOS disease spectrum. This simple risk score has the potential to 74 
assist in diagnosis, severity prediction of the disease risk stratification of PCOS women.  75 
 Methods 76 
Study population 77 
This was a cross sectional study involving 111 well characterised women with PCOS and 67 78 
women without PCOS who presented sequentially and prospectively at the Department of 79 
Academic Diabetes, Endocrinology and Metabolism. All patients gave written informed 80 
consent. This study was approved by the Newcastle & North Tyneside Ethics committee 81 
(ISRCTN70196169) and was conducted in accordance to the Declaration of Helsinki and 82 
local regulations. The diagnosis of PCOS was based on at least two out of three of the 83 
diagnostic criteria of the Rotterdam consensus, namely clinical and biochemical evidence of 84 
hyperandrogenism (Ferriman-Gallwey score >8; free androgen index >4, total 85 
testosterone >1.5 nmol/l), oligomenorrhea or amenorrhea and polycystic ovaries on 86 
transvaginal ultrasound. Non-classical 21-hydroxylase deficiency, hyperprolactinemia, 87 
Cushing’s disease and androgen-secreting tumours were excluded by appropriate tests. The 88 
study and study measurements are described in detail in our previous publication(8) . In 89 
summary we measured body mass index (BMI) (kg/m2), waist circumference (cm), hip 90 
circumference (cm), AMH (pmol/l), salivary testosterone (pmol/l), total testosterone (nmol/L),  91 
salivary androstenedione (pmol/l), serum androstenedione (nmol/L), SHBG (nmol/L) , FAI 92 
(%) , follicle stimulating hormone (FSH) (IU/L), Leutenizing hormone (LH) (IU/L) , fasting 93 
glucose (mmol/L), 2-Hour glucose (mmol/L), insulin (µIU/ml) according to established 94 
protocols in women with PCOS and controls. We also ascertained oral contraceptive use and 95 






























































history of menstrual irregularity/amenorrhoea. All of the control women had regular periods, 96 
no clinical or biochemical hyperandrogenism, no polycystic ovaries on ultrasound, no 97 
significant background medical history and none of them were on any medications including 98 
oral contraceptive pills or over the counter medications 99 
Study measurements 100 
Blood samples were centrifuged within 5 min of collection and were stored frozen at −80 °C 101 
pending analysis. All study measurements and analysis were performed in accordance with 102 
the relevant guidelines and regulations. Serum T and A were measured by LC/MS/MS on an 103 
Acquity UPLC system coupled to a Quattro Premier XE mass spectrometer (Waters, 104 
Manchester, UK). Sex hormone binding globulin (SHBG) was measured by an immunometric 105 
assay with fluorescence detection on the DPC Immulite 2000 analyzer using the 106 
manufacturer’s recommended protocol (upper limit of the reference range 2.0 nmol/l). The 107 
free androgen index (FAI) was calculated as the total testosterone × 100/SHBG. Serum 108 
insulin was assayed using a competitive chemiluminescent immunoassay performed on the 109 
manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). The analytical 110 
sensitivity of the insulin assay was 2 µU/ml, the coefficient of variation was 6%, and there 111 
was no stated cross-reactivity with proinsulin. Plasma glucose was measured using a 112 
Synchron LX 20 analyzer (Beckman-Coulter), using the manufacturer’s recommended 113 
protocol. The coefficient of variation for the assay was 1.2% at a mean glucose value of 114 
5.3 mmol/liter. The insulin resistance was calculated using the HOMA method [HOMA-115 
IR = (insulin × glucose)/22.5]. Anti-Müllerian hormone was measured using a Beckman 116 
Coulter Access automated immunoassay. A number of AMH immunoassays have been 117 
developed: we used the Beckman Coulter Access automated immunoassay from Beckman 118 
Coulter, as studies have shown good correlation between the Gen II ,Elecsys assays and the 119 
new Acesss AMH assay(10). 17-OHP was measured in the early morning sample and if on 120 






























































the higher side of the normogram, congenital adrenal hyperplasia was excluded with ACTH 121 
stimulation test. The free androgen index (FAI) was calculated as the total 122 
testosterone × 100/SHBG 123 
 124 
Collection and handling of saliva samples 125 
This has been detailed previously for the saliva collection and for the salivary androgen 126 
measurement methodology7. In brief, participants were asked to spit or drool directly into a 127 
4 mL sealable polystyrene tube and to provide at least 3 mL of saliva. Unstimulated saliva 128 
samples were used to avoid any assay interference. The “passive drool” technique was used 129 
for the collection of saliva rather than the ‘salivette’ method. Salivary testosterone and 130 
salivary androstendione were measured by LC-MS/MS analysis performed using a Waters 131 
Acquity UPLC system coupled to a Waters Xevo TQS mass spectrometer, giving a lower limit 132 
of quantification of 5 pmol/L for salT and 6.25 pmol/l for salA with an inter and intra-assay 133 
precision coefficient of variation of <4% and <7.5%, respectively. 134 
 135 
Statistical analysis 136 
All the study variables were log transformed if they were not normally distributed. After the 137 
log transformation we imputed the missing values using an iterative imputation method 138 
missForest (11) . missForest is an implementation of random forest algorithm. It is a non-139 
parametric imputation method, which builds a random forest model for each variable and 140 
subsequently uses the model to predict missing values in the variable with the help of 141 
observed values. To evaluate androgen levels between PCOS cases and controls, univariate 142 
comparative analyses were performed using the non-parametric Mann-Whitney tests on the 143 
imputed datasets. Means (standard deviations) or medians (interquartile range) were used to 144 






























































summarize continuous variables as appropriate while proportions and frequencies were used 145 
to summarize categorical variables. 146 
Risk prediction 147 
In logistic regression models, if the sample size is small or if a predictor is strongly 148 
associated with one of the possible outcomes the estimated coefficients may be biased. To 149 
overcome this issue, we used logistic regression model with Firth’s bias-adjusted estimates. 150 
The basic idea of the Firth’s logistic regression (Firth 1993) is to introduce a more effective 151 
score function by adding a term that counteracts the first-order term from the asymptotic 152 
expansion of the bias of the maximum likelihood estimation—and the term will go to zero as 153 
the sample size increases (12). Model selection with Firth’s bias adjustments was done using 154 
R package ‘logistf’ (12). Firstly, we included all the relevant variables in a model  such as age, 155 
BMI, waist-circumference, menstrual irregularity (yes/no), use of oral contraceptives (yes/no), 156 
serum testosterone, salivary testosterone, serum androstenedione, salivary androstenedione, 157 
oestradiol, SHBG, DHEAS, LH, FSH, Prolactin, 17-OHP, FAI and AMH levels. We did not 158 
include menstrual disturbances in the model as it is extremely difficult to quantify the extent 159 
duration and severity of menstrual disturbances and simply entering a yes/no variable can 160 
lead to model overfitting.   Next, we used backward in logistf in R to identify best model 161 
from a set of candidate predictor variables by entering predictors based on p value cut-off of 162 
0.05. The variable selection in logistf is simply performed by repeatedly calling add 1 or drop 163 
1 methods for logistf and is based on penalized likelihood ratio test. In order to assess the 164 
stability of the model thus obtained compared this stepwise model based on P-values to a 165 
model using forward selection. As the apparent predictive performance (performance in the 166 
development cohort) usually overestimates the performance in other patients, owing to 167 
overfitting and peculiarities in the development cohort (13), we internally validated the model 168 
through bootstrapping using package boot in R. A bootstrap analysis with 1000 simulations 169 






























































was performed to compare the measures of effect obtained from the original model with the 170 
bootstrapped model. 171 
We assessed model discrimination using area under the receiver operator curve (AUC) in a 172 
logistic regression model. Values greater than 0.7 indicate good predictive performance and 173 
values greater than 0.8 indicate excellent predictive performance of the model. Goodness-of-174 
fit were assessed using calibration plot and Hosmer-Lemeshow statistics. 175 
In order to calculate an individual patient’s risk of having PCOS, we first calculated their 176 
prognostic index (14) (PI). To achieve this, the estimated coefficients were multiplied by the 177 
values of the predictor variables of the patient and the sum of these multiplications were 178 
added to the intercept of the model. Using the PI we then calculated the risk of PCOS as 179 
exp(PI)/(1+exp(PI)). 180 
For ease of interpretation we back-transformed the significant variables retained in the model 181 
and presented the effect estimates and P-values associated with these. We did a sensitivity 182 
analysis using 1) untransformed raw variables with missing values and 2) untransformed raw 183 
variables with imputed values to assess model stability. 184 
Results 185 
The anthropometric and hormonal characteristics of women with PCOS and controls from the 186 
Hull UK PCOS biobank are shown in Table 1. Women with PCOS were younger (P=0.01) 187 
had higher BMI (P<0.0001), waist circumference (P<0.0001), and overall, greater levels of 188 
all markers indicating hyperandrogenemia compared to controls. Women with PCOS also had 189 
significantly higher levels of 17-OHP (P=0.03) and AMH (P<0.0001). 190 
The logistic regression with backward selection model revealed four variables independently 191 
associated with PCOS namely, FAI [Beta 0.30(0.12), P=0.008)], 17-OHP [Beta=0.20(0.01), 192 
P=0.026], AMH [Beta=0.04(0.01), P<0.0001], and waist-circumference [Beta=0.08(0.02), 193 






























































P<0.0001] (Table 2). Relaxation and restriction of the removal criterion for backward 194 
selection to P<0.20 and P<0.10, respectively, did not change the final model. Similar results 195 
were also seen in a model with forward selection. A bootstrap analysis with 1000 simulations 196 
indicated minimal bias and model optimism in estimated effect sizes (Supplementary table 197 
1).  Bootstrap estimates of several discrimination indices to quantify the model are presented 198 
in Supplementary Table 2. The optimism corrected estimate of the Somers’ D was 0.81 199 
(Supplementary Table 2) with a corresponding bias corrected c-statistic of ((1+0.8193)/2) = 200 
0.90. The model with the 4 predictor variables had a high discrimination ability with a c-201 
statistics of AUC=0.91 (0.88-0.95). The AUCs for FAI, AMH, 17-OHP and WC were 0.81 202 
(0.75-0.87), 0.75 (0.68-0.82), 0.59 (0.51-0.67) and 0.91(0.88-0.95), respectively (Figures 1a-203 
1e). Model calibration was assessed using the Hosmer–Lemeshow statistics and a calibration 204 
plot (Fig 2). The model shows good calibration with Hosmer–Lemeshow chi-squared of 205 
3.7865, and a p-value of 0.87. 206 
Based on the penalised regression coefficient, we calculated a prognostic index (PI) for each 207 
of the PCOS cases using the formula                                                                                                                              208 
(-9.77 + (0.07*WC) + (0.04*AMH) + (0.3*FAI) + (0.01*17OHP)) and calculated a risk score 209 
for each case of PCOS with formula exp(PI)/(1+exp(PI))*100. The metabolic profile of 210 
women with PCOS in the top 3 quartiles (q1-q3) of this risk score (classified as low-risk 211 
score) was compared with the metabolic profile of PCOS women in the bottom quartile (q4) 212 
of the risk score (classified as high risk score). PCOS women with a high risk score, had a 213 
worse metabolic profile with significantly higher 2-hour glucose (P=0.01), baseline insulin 214 
(P=0.0003), TG (P=0.0005) and CRP (<0.0001) levels and lower HDL-C levels (P=0.02), as 215 
compared to those with a low-risk score (Table 3).  We have constructed a mobile phone 216 
application for easy usage of this risk score in clinical settings. (Supplementary Figure 1) 217 
Discussion 218 






























































 The diagnosis of PCOS is often challenging given the wide range of hormonal markers and 219 
derived indices used to measure hyperandrogenism and variations in clinical presentations. 220 
We developed and internally validated a simple 4-variable model (i.e., FAI, 17-OHP, AMH 221 
and waist circumference) for predicting the risk of having PCOS in clinical settings. This 222 
model showed good discrimination ability and good calibration.  Each of the 4 variables 223 
reported in our model have been previously associated with PCOS (6, 9, 15-17).   224 
In line with differential diagnoses of conditions causing hyperandrogenism in females, in this 225 
we measured 17-OHP levels to rule out a potential diagnosis of non-classical congenital 226 
adrenal hyperplasia (NCCAH), which is another disorder of hyperandrogenism. The normal 227 
levels of 17-OHP in females are well defined and the baseline mean level of 17-OHP in those 228 
with NCCAH is around 20 ng/ml (60 nmol/L) (18). In this study the PCOS women had mean 229 
baseline 17-OHP levels of 1.6ng/ml (5 nmol/L) safely ruling out NCCAH. A baseline 17-230 
OHP cut-off of 2ng/ml is suggested for the screening NCCAH, however, it is not unusual for 231 
patients with PCOS to have levels of 17-OHP higher than this cut-off.  A study by Pall et.al 232 
(19) comparing the 17-OHP levels in PCOS and NCCAH showed that 25% of lean patients 233 
with PCOS, 21% of obese patients with PCOS, and 7% of controls had basal 17-OHP levels 234 
above the cut-off level 2 ng/ml. Patients with PCOS have also been showed to have higher 235 
17-OHP levels as compared to those without PCOS (17). For example, 17-OHP levels have 236 
been shown to be significantly higher in pre- and postmenopausal PCOS women as compared 237 
to controls(15, 16) , with the levels being highest in those with severe phenotype of PCOS 238 
(15)  Interestingly, a subgroup of PCOS patients with exaggerated 17-OHP response to 239 
GnRH agonist presented with severe hyperandrogenemia, glucose-stimulated β-cell insulin 240 
secretion, and worse insulin resistance (20). The excess 17-OHP in patients with PCOS is 241 
thought to be of the result of excess stimulation of theca interna cells- by luteinizing hormone 242 
(LH)(15). In this study, for the first time, we showed that 17-OHP are independently 243 






























































associated with PCOS, after adjustments of FAI, AMH and waist circumference. However, 244 
the discriminatory capacity of 17-OHP to detect PCOS were small and if not readily available, 245 
can be excluded from the model. 246 
We also show that AMH was independently associated with PCOS diagnosis after 247 
adjustments for FAI, WC and 17-OHP.  AMH is produced in the granulosa cells by the 248 
preantral and small antral follicles and it appears to inhibit the action of FSH on aromatase, 249 
and therefore, it contributes to the development of a single follicle for ovulation (21) . AMH 250 
is elevated in PCOS due to the increased count of small antral follicle and increased secretion 251 
of AMH per follicle (22) . We have recently shown that those with raised AMH have up to 4-252 
fold increased risk of having PCOS(8) . It has also been suggested that serum AMH reflects 253 
ovarian size in PCOS patients and can be used as surrogate for transvaginal ultrasound in the 254 
diagnosis of PCOS (9).   255 
The associations of FAI and waist circumference with PCOS are well-documented in the 256 
literature (6, 23) . Waist circumference, a measure of central adiposity,  is a marker of 257 
severity of PCOS and has been suggested to be a better surrogate of glucose and lipid 258 
metabolism in PCOS than the disease status per se (23) .  Menstrual dysfunction is a common 259 
symptom in PCOS and is a consequence of anovulation. Ovulatory dysfunction can also be 260 
seen in women who have regular menstrual cycle (24) (25) and as a result menstrual history 261 
alone is insufficient in defining PCOS. The prevalence of non-specific menstrual dysfunction 262 
in high in women, especially in adolescent population where it can be as high has 30%, 1 263 
year post menarche (26). It is difficult to identify real anovulation related menstrual 264 
dysfunction and many of the women are already on oral-contraceptive pills which makes it 265 
difficult to ascertain the history of menstrual dysfunction. Hence we decided not to include 266 
this variable in our model.  267 






























































In this study we showed that those with a high  risk score derived from a model, which 268 
included waist circumference, FAI , AMH and 17-OHP, had a poor metabolic profile, as 269 
evidenced by a higher 2h-glucose , raised TG levels, basal insulin, CRP and lower HDL-270 
cholesterol. Thus, this risk score can not only identify patients who are at high risk of PCOS, 271 
but it can also risk stratify patients and identify those who are more likely to experience 272 
adverse PCOS-related metabolic outcomes.  Collectively, the four variables in our model 273 
capture the full spectrum of PCOS, wherein, FAI reflects androgens excess, AMH grasps the 274 
ovarian size and/or follicle count, 17-OHP represents the alteration in LH-FSH ratio and WC 275 
indicates the presence of metabolic abnormalities in PCOS. FAI, free testosterone and SHBG 276 
are routinely measured as a part of the diagnostic workup for PCOS, while 17-OHP is 277 
measured as per the endocrine society guidelines to rule out congenital adrenal hyperplasia. 278 
AMH measurement is routinely done in these patients as a part of their fertility work-up, 279 
hence, no additional testing is required when this model is used. On the other hand, using this 280 
model, may eliminate the need for testing additional androgen markers such as salivary 281 
testosterone and androstenedione, and hence, it can reduce the cost associated with these tests. 282 
Given the high prevalence of metabolic syndrome in PCOS, guidelines issued by the 283 
American College of Obstetricians and Gynaecologists and the Endocrine Society 284 
recommend that all women with PCOS should undergo screening for impaired glucose 285 
tolerance and dyslipidaemia with a 2 hour 75 g oral glucose tolerance test and fasting lipid 286 
profile upon diagnosis, with repeat screening of each test every 2-5 years (27). However, 287 
there is no guidance on how to identify women who are at high risk for developing metabolic 288 
syndrome and not all women with PCOS get metabolic syndrome screening in primary or 289 
secondary care. The advantage of this scoring system is that it may assist in the diagnosis of 290 
PCOS and highlights those women who are at high risk of developing metabolic syndrome to 291 
help prevent future metabolic complications. 292 






























































Our study has several limitations. Our 4 variable risk model for PCOS is not externally 293 
validated. We have attempted to overcome this problem by bootstrapping, and the effects size 294 
of our model indicate very little optimism and good calibration. However, further external 295 
validation of this model in an ethnically diverse population is warranted. Secondly, although 296 
the mean levels of 17-OHP in our study are significantly lower than those seen in patients 297 
with CAH and NCCAH, it is possible to have NCCAH with a normal 17-OHP level.  The 298 
sample size of our study was modest with 111 PCOS and 67 controls. However, this a very 299 
well characterized cohort of PCOS- and control women which measures all the androgen and 300 
related markers (including salivary markers) and unique in the sense that all the participants 301 
had classical PCOS whereby all the three criteria for diagnosis of PCOS namely 302 
oligomenorrhea, hyperandrogenism, and PCO morphology on ultrasound were met. 303 
Nonetheless, this model will need further validation in large prospective cohorts from 304 
different ethnicities for its validation.  Another limitation of our study is that all the patients 305 
in our study had Classical PCOS oligomenorrhea, hyperandrogenism, and PCOS as 306 
designated in the Rotterdam criteria. The other sub-phenotypes include ovulatory PCOS 307 
(hyperandrogenism, PCO, and regular menstrual cycles), non-PCO PCOS (oligomenorrhea, 308 
hyperandrogenism, and normal ovaries) and mild PCOS (oligomenorrhea, PCO, and normal 309 
androgens). Hence we were not able to evaluate our model for the other 3 phenotypes. 310 
However, the classical PCOS phenotype represents the largest subgroup of patients with 311 
PCOS, with an estimated prevalence of up to 80% amongst the PCOS population (28) and 312 
this model can be generalised to the largest subgroup of the PCOS population. The strength 313 
of the study on the other hand is that it provides a simple 4 variable model and calculator 314 
which can predict the risk of PCOS in clinical settings and identify those with unfavourable 315 
PCOS-related metabolic consequences. Furthermore, this study consisted of a homogenous 316 






























































group of Caucasian women who fulfilled Rotterdam diagnostic criteria of PCOS, thus 317 
providing a robust database for model development.  318 
Conclusions 319 
In summary, we have developed a simple model consisting of FAI, 17-OHP, AMH and waist 320 
circumference for risk prediction and risk stratification in PCOS, with these variables 321 
previously associated with PCOS This model will have to be externally validated in 322 
populations across different ethnicities before a widespread clinical application. 323 
 324 
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 400 
Figure legends 401 
Figure 1: Graphs showing AUC for for Antimullerian Hormone (AMH); Free Androgen Index (FAI); 17-OHP, 17α-Hydroxyprogesterone and 402 
waist circumference (WC) individually and combined. The c-statistics for the complete model was 0.91(0.88-0.95) 403 
Figure 2: Graph showing a plot of the expected event probabilities against the predicted event probabilities with a perfect predictive ability 404 











































































Table 1: Baseline characteristics and hormonal parameters of women with and without PCOS in the Hull UK PCOS biobank 418 
  PCOS (n=67) Control (n=111) P-value* 
  Median (IQR) Median (IQR)   
Age 27.68 (11) 29.92 (11) 0.01  
BMI 34.15 (9.9) 26.86 (6.2) <0.0001   
Waist Circumference (cm) 101 (21.2) 78 (14.5) <0.0001  
Testosterone (nmol/L) 1.30 (0.85) 0.94 (0.45) <0.0001   
Salivary Androstenedione (pmol/L) 146.4 (88.65) 185.8 (112.4) 0.0002  
Oestradiol (pmol/)L 190 (295) 180 (165)  0.43 
SHBG (nmol/L) 27 (18) 47 (31) <0.0001    
TSH (mU/L) 1.9 (1.2) 1.5 (1.1)  0.03 
DHEAS (umol/l) 5.2 (3.8) 4.6 (4) 0.04  
Androstenedione  (nmol/L) 9.5 (5.8) 7.3 (4.4) <0.0001     
Prolactin 250 (165) 260 (126) 0.68  
LH 6.2 (5.6) 4.1 (4.3) 0.003  
FSH 4.9 (2.7) 5.5 (3.2) 0.09  
FAI 4.5 (4.8) 1.98 (1.4)  <0.0001    
17-OHP (nmol/L) 4.4 (3) 3.9 (2)  0.03 
AMH 37 (41) 18.1 (24.5) <0.0001  
* P-values based on Mann–Whitney U test 419 






























































AMH, Antimullerian Hormone; BMI, Body Mass Index; DEAS, Dehydroepiandrosterone, FAI, Free Androgen Index; FSH, Follicle Stimulating 420 
Hormone; LH, Luteinizing hormone; SHBG, sex hormone-binding globulin; TSH. Thyroid Stimulating Hormone; 17-OHP, 17α-421 




Table 2: Independent predictors of PCOS from penalized logistic regression model 426 
GLM based Logistic regression 
estimates 
Firth's Penalised logistic regression 
estimates 
Beta SE P-value Beta SE P-value 
FAI 0.32 0.12 0.008 0.30 0.12 0.008 
17-OHP 0.21 0.09 0.026 0.20 0.09 0.026 
AMH 0.04 0.01 <0.0001 0.04 0.01 <0.0001 
Waist Circumference 0.08 0.01 0.0003 0.07 0.02 <0.0001 
AMH, Antimullerian Hormone; FAI, Free Androgen Index; 17-OHP, 17α-Hydroxyprogesterone. 427 
 428 
 429 
Table 3: Metabolic Profile of PCOS patients with low (q1-q3) and high risk (q4) score based on penalised regression model 430 
PCOS Cases with low 
risk score (Q1-Q3) 
(n=84) 
PCOS cases with high-
risk score (Q4) 
(n=27) P-value 
Mean (SD) Mean (SD) 
Baseline Glucose 4.73 (0.48) 5.19 (1.91) 0.41 
2-Hour Glucose 5.51 (1.30) 7.73 (3.39) 0.01 
Insulin 13.01 (8.27) 27.25 (21.98) 0.0003 






































































LDL, Low density lipoprotein; HDL, high density lipoprotein; TG, Triglycerides; TC: Total Cholesterol and CRP, C-reactive protein*P-values 439 
based on Mann–Whitney U test 440 
LDL-c 2.88 (0.90) 2.99 (0.73) 0.94 
HDL-c 1.26 (0.32) 1.10 (0.18) 0.02 
TG 1.26 (0.62) 2.46 (2.22) 0.0005 
TC 4.72 (0.98) 4.95 (0.95) 0.19 
CRP 3.64 (3.73) 8.45 (6.61) <0.0001 






























































Figure 1: Receiver Operator curves for Antimullerian Hormone (AMH); Free Androgen Index (FAI); 17-OHP, 17α-Hydroxyprogesterone and waist 441 





 Fig 1b , 
AUC=0.59 (0.51-0.67) 
 Fig 1c 
AUC=0.75 (0.68-0.82) 
 Fig 1d , 
AUC=0.82 (0.76-0.88) 
 
Fig 1e  AUC =0.91(0.88-0.95) 

































































































































Supplementary Table 1: Estimates of bias for logistic regression model from 1000 
bootstrap estimates 
Original Bias 
FAI 0.30 0.029 
17-OHP 0.20 0.002 
AMH 0.08 0.002 
Waist Circumference 0.04 0.001 





Supplementary Table 2: Bootstrap estimates of several discrimination indexes to 
quantify the model 
 
index.orig training test optimism index.corrected n 
Dxy 0.8384 0.8442 0.8252 0.019 0.8193 1000 
R2 0.6297 0.6461 0.616 0.0301 0.5995 1000 
Intercept 0 0 -0.003 0.003 -0.003 1000 
Slope 1 1 0.9185 0.0815 0.9185 1000 
Emax 0 0 0.0195 0.0195 0.0195 1000 
D 0.6147 0.6386 0.5963 0.0422 0.5725 1000 
U -0.0112 -0.0112 0.0034 -0.0146 0.0034 1000 
Q 0.6259 0.6498 0.5929 0.0569 0.5691 1000 
B 0.1161 0.1107 0.1209 -0.0101 0.1262 1000 
g 3.5059 3.8221 3.4621 0.36 3.1459 1000 









































































Supplementary Figure 1: Phone based PCOS risk calculator application 
 































































We are thankful to the reviewers for their useful comments. This has certainly increased the 




1-No enough information regarding the women without PCOS was given. They need to 
explain the method via they selected the control women. 
Response: We are thankful to reviewers for pointing this out. We have addressed this by 
including the following in the methods section (lines 95-98) 
“All of the control women had regular periods, no clinical or biochemical 
hyperandrogenism, no polycystic ovaries on ultrasound, no significant background medical 
history and none of them were on any medications including oral contraceptive pills or over 
the counter medications.  
 
2-FAI should be defined for non-endocrinologist readers. 
Thanks. We have now addressed this by including the following in the methods section. 
(lines 120-121) 
“The free androgen index (FAI) was calculated as the total testosterone × 100/SHBG” 
 
3-17OHP is a well-known marker in the diagnosis of NCAH due to 21OH deficiency. It 
should be measured early in the morning and during early follicular phase in order to 
rule out the adrenal contribution. So, the details about the measurement of 17OHP are 
necessary and it should be given in Method section. 
 
Response: We have now included a study measurements section which addresses this. 17-
OHP was measured as a part of early morning sample and if on the higher side was excluded 
CAH was excluded with ACTH stimulation test. We have included following paragraphs in 
the methods sections. (lines 99-132) 
 
Blood samples were centrifuged within 5 min of collection and were stored frozen at −80 °C 
pending analysis. All study measurements and analysis were performed in accordance with 
the relevant guidelines and regulations. Serum T and A were measured by LC/MS/MS on an 
Acquity UPLC system coupled to a Quattro Premier XE mass spectrometer (Waters, 
Manchester, UK). Sex hormone binding globulin (SHBG) was measured by an immunometric 
assay with fluorescence detection on the DPC Immulite 2000 analyzer using the 
manufacturer’s recommended protocol (upper limit of the reference range 2.0 nmol/l). The 
free androgen index (FAI) was calculated as the total testosterone × 100/SHBG. Serum 
insulin was assayed using a competitive chemiluminescent immunoassay performed on the 






























































manufacturer’s DPC Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). The analytical 
sensitivity of the insulin assay was 2 µU/ml, the coefficient of variation was 6%, and there 
was no stated cross-reactivity with proinsulin. Plasma glucose was measured using a 
Synchron LX 20 analyzer (Beckman-Coulter), using the manufacturer’s recommended 
protocol. The coefficient of variation for the assay was 1.2% at a mean glucose value of 
5.3 mmol/liter. The insulin resistance was calculated using the HOMA method [HOMA-
IR = (insulin × glucose)/22.5]. Anti-Müllerian hormone was measured using a Beckman 
Coulter Access automated immunoassay. A number of AMH immunoassays have been 
developed: we used the Beckman Coulter Access automated immunoassay from Beckman 
Coulter, as studies have shown good correlation between the Gen II ,Elecsys assays and the 
new Acesss AMH assay (Reprod Biol Endocrinol. 2016 Kylie Pearson). 17-OHP was 
measured in the early morning sample and if on the higher side of the normogram, congenital 
adrenal hyperplasia was excluded with ACTH stimulation test. The free androgen index 
(FAI) was calculated as the total testosterone × 100/SHBG 
 
Collection and handling of saliva samples 
This has been detailed previously for the saliva collection and for the salivary androgen 
measurement methodology7. In brief, participants were asked to spit or drool directly into a 
4 mL sealable polystyrene tube and to provide at least 3 mL of saliva. Unstimulated saliva 
samples were used to avoid any assay interference. The “passive drool” technique was used 
for the collection of saliva rather than the ‘salivette’ method. Salivary testosterone and 
salivary androstendione were measured by LC-MS/MS analysis performed using a Waters 
Acquity UPLC system coupled to a Waters Xevo TQS mass spectrometer, giving a lower limit 
of quantification of 5 pmol/L for salT and 6.25 pmol/l for salA with an inter and intra-assay 
precision coefficient of variation of <4% and <7.5%, respectively. 
 
 
4-As far as I know there is no perfect method for measurement of AMH. Do the authors 
think that this a problem in the development of such a model? 
A number of AMH immunoassays have been developed and they show good correlation with 
each other. We have used the new Beckman Coulter Access automated immunoassay from 
Beckman Coulter which shows good correlation with the other commonly used assays. We 
have addressed this comment by including the following it the methods section. (Lines 115-
119) 
A number of AMH immunoassays have been developed: we used the Beckman Coulter Access 
automated immunoassay from Beckman Coulter, as studies have shown good correlation 
between the Gen II ,Elecsys assays and the new Acesss AMH assay (Reprod Biol Endocrinol. 
2016 Kylie Pearson).  
5-According to the model developed by the authors, the following hormones should be 
measured:17-OHP, AMH, SHBG and total testosterone, the last two for the calculation 
of FAI. I am wondering whether this model is feasible or not in clinical practice. 






























































Response: FAI, free testosterone and SHBG are routinely measured as a part of diagnostic 
workup for PCOS, while 17-OHP is measured as per the Endocrine society guidelines to rule 
out congenital adrenal hyperplasia. AMH on the other hand is routinely done in these patients 
as a part of their fertility work-up; therefore, no additional testing is required when this model 
is used. Hence using this model does not require any additional testing and can be used in 
clinical practice. 
 
6-Do the authors make a comment about the cost-effectiveness of the model?  
Response: FAI, free testosterone and SHBG are routinely measured as a part of diagnosis for 
PCOS, while 17-OHP is measured as per the Endocrine society guidelines to rule out 
Congenital adrenal hyperplasia. AMH on the other hand is routinely done in these patients as 
a part of fertility work-up; therefore, no additional testing is required when this model is 
used. On the other hand, using this model, eliminates the need for testing additional androgen 
markers such as salivary testosterone, androstenedione and hence, it can reduce the cost 
associated with these tests. We have not formally measured the cost-effectiveness of this 
model - but believe that no additional costs will be required to implement this model as all 
the 3 tests are done routinely in women with PCOS in most centres. 
We have address the comments 5 and 6 by including the following in the discussion section 
(lines 273-279) 
“FAI, free testosterone and SHBG are routinely measured as a part of the diagnostic workup 
for PCOS, while 17-OHP is measured as per the Endocrine society guidelines to rule out 
congenital adrenal hyperplasia. AMH measurement is routinely done in these patients as a 
part of their fertility work-up, hence, no additional testing is required when this model is 
used. On the other hand, using this model, may eliminate the need for testing additional 
androgen markers such as salivary testosterone and androstenedione, and hence, it can 
reduce the cost associated with these tests”.  
 
 
7-They suggest that this simple 4 variable model identifies unfavourable PCOS-related 
metabolic consequences. Can they say that we will be able to decide whether metabolic 
parameters in PCOS patients should be measured or not when we used the model? If 
no, what about the advantages of the model? 
Response: Given the high prevalence of metabolic syndrome in PCOS, guidelines issued by 
the American College of Obstetricians and Gynecologists and the Endocrine Society 
recommend that all women with PCOS undergo screening for impaired glucose tolerance and 
dyslipidemia with a 2 hour 75 g oral glucose tolerance test and have a fasting lipid profile 
upon diagnosis, with repeat screening of each test every 2-5 years. However, there is no 
guidance on how to identify women who are at high risk for developing metabolic syndrome 
and not all women with PCOS get metabolic syndrome screening in primary or secondary 
care. There is an ongoing debate if we should be screening all pregnant women for Type 2 
diabetes.  The advantage of this scoring system is that it can highlight the women who are at 
high risk of developing metabolic syndrome to help prevent future metabolic complications 
in those women.  






























































We have addressed the above comment by including the following paragraph in the 
discussion: (lines 280-289) 
“Given the high prevalence of metabolic syndrome in PCOS, guidelines issued by the 
American College of Obstetricians and Gynaecologists and the Endocrine Society 
recommend that all women with PCOS should undergo screening for impaired glucose 
tolerance and dyslipidaemia with a 2 hour 75 g oral glucose tolerance test and fasting lipid 
profile upon diagnosis, with repeat screening of each test every 2-5 years. (Kelsey E. S. 
Salley The Journal of Clinical Endocrinology & Metabolism 2007). However, there is no 
guidance on how to identify women who are at high risk for developing metabolic syndrome 
and not all women with PCOS get metabolic syndrome screening in primary or secondary 
care. The advantage of this scoring system is that it may assist in the diagnosis of PCOS and 
highlights those women who are at high risk of developing metabolic syndrome to help 
prevent future metabolic complications.” 
 
8- There are some minor grammatical errors such as; page 10, line 198, showed should 
be shown. 




1) The study is quite small, with only 111 PCOS and 67 controls. Hence, it is 
unclear how powerful will the analysis be.  
Response:  We acknowledge that the sample size in our study is small. However, this a very 
well characterized cohort of PCOS- which measures all the androgen and related markers 
(including salivary markers) and unique in the sense that all the participants had classical 
PCOS whereby all the three criteria for diagnosis of PCOS oligomenorrhea, 
hyperandrogenism, and PCOS on ultrasound were met. A post-hoc power calculation (using 
the function pwr.f2.test in the R package pwr) shows that in order to replicate this model 
(with adjusted r-squared of 0.35) a sample size of 60 cases and 60 controls will give us more 
than 90% power to replicate the findings. So our discovery cohort seems to be adequately 
powered.  However, we do acknowledge the need to replicate and validate this model in 
larger prospective cohorts and have addressed this in the paper- by including the following 
(Lines 295-301) 
“The sample size of our study was modest with 111 PCOS and 67 controls. However, this 
a very well characterized cohort of PCOS- and control women which measures all the 
androgen and related markers (including salivary markers) and unique in the sense that 
all the participants had classical PCOS whereby all the three criteria for diagnosis of 
PCOS namely oligomenorrhea, hyperandrogenism, and PCO morphology on ultrasound 
were met. Nonetheless, this model will need further validation in large prospective 
cohorts from different ethnicities for its validation”. 































































2)  It is unclear what the phenotypes of the PCOS patients that were included are. 
As the investigators know, the Rotterdam criterion denotes 4 phenotypes (A-D). The 
predictors/diagnostic markers of each of these phenotypes vary. The investigators 
need to consider PCOS phenotype in their exercise. 
Response: The reviewer has rightly pointed out that there are 4 subtypes of PCOS based on 
Rotterdam criterion. The Rotterdam and AE-PCOS Society criteria recognize at least 4 
unique clinical phenotypes: (A) Classical PCOS (oligomenorrhea, hyperandrogenism, and 
PCO), (B) Ovulatory PCOS (hyperandrogenism, PCO, and regular menstrual cycles), and (C) 
Non-PCO PCOS (oligomenorrhea, hyperandrogenism, and normal ovaries) (D) mild PCOS 
(oligomenorrhea, PCO, and normal androgens) 
All the patients in or study had the phenotype A- Classical PCOS- and the diagnosis of PCOS 
in our study was based on all three diagnostic criteria of the Rotterdam consensus, namely 
clinical and biochemical evidence of hyperandrogenism (Ferriman-Gallwey score >8; free 
androgen index >4, total testosterone >1.5 nmol/l), oligomenorrhea or amenorrhea and 
polycystic ovaries on transvaginal ultrasound. 
The prevalence of classical PCOS is reported to be up to 70% of PCOS population (Reprod 
Sci. 2014 Nina M. Clark) and hence the findings of our study can be generalised to the most 
prevalent phenotype of PCOS. Since our study population consisted of phenotype A, we are 
not able to do a subgroup analysis with various sub-groups of PCOS and we have 
acknowledged this limitation in our discussion section by adding the following paragraph. 
(lines 302-310) 
“Another limitation of our study is that all the patients in our study had Classical PCOS 
oligomenorrhea, hyperandrogenism, and PCOS as designated in the Rotterdam criteria. 
The other sub-phenotypes include ovulatory PCOS (hyperandrogenism, PCO, and 
regular menstrual cycles), non-PCO PCOS (oligomenorrhea, hyperandrogenism, and 
normal ovaries) and mild PCOS (oligomenorrhea, PCO, and normal androgens). Hence 
we were not able to evaluate our model for the other 3 phenotypes. However, the 
classical PCOS phenotype represents the largest subgroup of patients with PCOS, with 
an estimated prevalence of up to 80% amongst the PCOS population (Reprod Sci. 2014 
Nina M. Clark) and this model can be generalised to the largest subgroup of the PCOS 
population” 
 
3) The attempt to develop predictive models for PCOS is not new. The problem is 
that if the predictive model is based on elements that require invasive testing (i.e. 
blood tests) or tests that are part of the diagnosis (i.e. androgens), then the 
predictive model is really a diagnostic model not a predictive model. As such the 
value of this exercise from a public health or predictive point of view is very 
limited.  Perhaps the investigators are attempting to determine what the minimal 
elements are for the diagnosis of PCOS – although this is already guided by the 
diagnostic criteria.  
 
 






























































Response: We agree with the reviewer that we proposed to determine the minimal elements 
required for the diagnosis of PCOS. The current guidelines do not specify which androgen 
markers should take precedence over the others and also do not include the new marker AMH 
that has been consistently shown to be associated with PCOS in several recent studies. Also, 
there is no specific guidance on how to identify women who are at high risk for developing 
metabolic syndrome in the future and not all women with PCOS get metabolic syndrome 
screening in primary or secondary care. So the overarching objective of the PCOS risk score 
was to identify the best available androgen and hormonal markers to assist in the diagnosis of 
PCOS (when other causes of hyperandrogenemia have been ruled out) and to identify women 
who are at higher risk of metabolic complications. We have now addressed this comment by 
including the following in the discussion section. (lines 280-289) 
“Given the high prevalence of metabolic syndrome in PCOS, guidelines issued by the 
American College of Obstetricians and Gynaecologists and the Endocrine Society 
recommend that all women with PCOS should undergo screening for impaired glucose 
tolerance and dyslipidaemia with a 2 hour 75 g oral glucose tolerance test and fasting lipid 
profile upon diagnosis, with repeat screening of each test every 2-5 years. (Kelsey E. S. 
Salley The Journal of Clinical Endocrinology & Metabolism 2007). However, there is no 
guidance on how to identify women who are at high risk for developing metabolic syndrome 
and not all women with PCOS get metabolic syndrome screening in primary or secondary 
care. The advantage of this scoring system is that it may assist in the diagnosis of PCOS and 
highlights those women who are at high risk of developing metabolic syndrome to help 
prevent future metabolic complications.”” 
 
 
4)    Minor:  
a.    It would be helpful to the reader if the investigators, even briefly, described the 
methods used hormonal measures, rather than fully referring to the reference #8. 
 
Response: Now we have included the complete methods used in the hormonal measures. 
(Lines 99-132) 
 
Blood samples were centrifuged within 5 min of collection and were stored frozen at 
−80 °C pending analysis. All study measurements and analysis were performed in 
accordance with the relevant guidelines and regulations. Serum T and A were 
measured by LC/MS/MS on an Acquity UPLC system coupled to a Quattro Premier 
XE mass spectrometer (Waters, Manchester, UK). Sex hormone binding globulin 
(SHBG) was measured by an immunometric assay with fluorescence detection on the 
DPC Immulite 2000 analyzer using the manufacturer’s recommended protocol 
(upper limit of the reference range 2.0 nmol/l). The free androgen index (FAI) was 
calculated as the total testosterone × 100/SHBG. Serum insulin was assayed using a 
competitive chemiluminescent immunoassay performed on the manufacturer’s DPC 
Immulite 2000 analyzer (Euro/DPC, Llanberis, UK). The analytical sensitivity of the 
insulin assay was 2 µU/ml, the coefficient of variation was 6%, and there was no 
stated cross-reactivity with proinsulin. Plasma glucose was measured using a 






























































Synchron LX 20 analyzer (Beckman-Coulter), using the manufacturer’s 
recommended protocol. The coefficient of variation for the assay was 1.2% at a 
mean glucose value of 5.3 mmol/liter. The insulin resistance was calculated using the 
HOMA method [HOMA-IR = (insulin × glucose)/22.5]. Anti-Müllerian hormone was 
measured using a Beckman Coulter Access automated immunoassay; between run 
precision was <3% across the range measured. 17-OHP was measured in the early 
morning sample and if on the higher side of normogram CAH was excluded with 
ACTH stimulation test. 
 
Collection and handling of saliva samples 
This has been detailed previously for the saliva collection and for the salivary 
androgen measurement methodology7. In brief, participants were asked to spit or 
drool directly into a 4 mL sealable polystyrene tube and to provide at least 3 mL of 
saliva. Unstimulated saliva samples were used to avoid any assay interference. The 
“passive drool” technique was used for the collection of saliva rather than the 
‘salivette’ method. Salivary testosterone and salivary androstendione were measured 
by LC-MS/MS analysis performed using a Waters Acquity UPLC system coupled to a 
Waters Xevo TQS mass spectrometer, giving a lower limit of quantification of 
5 pmol/L for salT and 6.25 pmol/l for salA with an inter and intra-assay precision 
coefficient of variation of <4% and <7.5%, respectively 
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